Abstract:Aims: Ablation of monomorphic ventricular tachycardia (MMVT) has been shown to reduce shock frequency and improve survival. We aimed to compare cause-specific risk factors for MMVT and polymorphic ventricular tachycardia (PVT)/ventricular fibrillation (VF) and to develop predictive models. Methods and results: The multicentre retrospective cohort study included 2668 patients (age 63.1 ± 13.0 years; 23% female; 78% white; 43% non-ischaemic cardiomyopathy; left ventricular ejection fraction 28.2 ± 11.1%). Cox models were adjusted for demographic characteristics, heart failure severity and treatment, device programming, and electrocardiogram metrics. Global electrical heterogeneity was measured by spatial QRS-T angle (QRSTa), spatial ventricular gradient elevation (SVGel), azimuth, magnitude (SVGmag), and sum absolute QRST integral (SAIQRST). We compared the out-of-sample performance of the lasso and elastic net for Cox proportional hazards and the Fine-Gray competing risk model. During a median follow-up of 4 years, 359 patients experienced their first sustained MMVT with appropriate implantable cardioverter-defibrillator (ICD) therapy, and 129 patients had their first PVT/VF with appropriate ICD shock. The risk of MMVT was associated with wider QRSTa [hazard ratio (HR) 1.16; 95% confidence interval (CI) 1.01-1.34], larger SVGel (HR 1.17; 95% CI 1.05-1.30), and smaller SVGmag (HR 0.74; 95% CI 0.63-0.86) and SAIQRST (HR 0.84; 95% CI 0.71-0.99). The best-performing 3-year competing risk Fine-Gray model for MMVT [time-dependent area under the receiver operating characteristic curve (ROC(t)AUC) 0.728; 95% CI 0.668-0.788] identified high-risk (> 50%) patients with 75% sensitivity and 65% specificity, and PVT/VF prediction model had ROC(t)AUC 0.915 (95% CI 0.868-0.962), both satisfactory calibration. Conclusion: We developed and validated models to predict the competing risks of MMVT or PVT/VF that could inform procedural planning and future randomized controlled trials of prophylactic ventricular tachycardia ablation. Clinical trial registration: URL:www.clinicaltrials.gov Unique identifier:NCT03210883.

Risk stratification and early prevention of malignant ventricular arrhythmia:rationale and design

Identification and management of high risk ventricular arrhythmias

The risk stratification in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy.

A Territory-Wide Study of Arrhythmogenic Right Ventricular Cardiomyopathy Patients from Hong Kong

Long-term outcomes in patients with arrhythmogenic right ventricular cardiomyopathy

Advances in Research of Arrhythmogenic Right Ventricular Cardiomyopathy

Mechanistic and Therapeutic Perspectives for Cardiac Arrhythmias: Beyond Ion Channels

P5-108: The clinical characteristics in Chinese patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: A report from China

Nonlinear Short-Term Heart Rate Variability Prediction of Spontaneous Ventricular Tachyarrhythmia

Present Situation of Treatment on Organic Cardiopathy Arrhythmia

Literature case analysis in Chinese patients with arrhythmogenic right ventricular cardiomyopathy

Long-Term Predictors of Mortality and Malignant Ventricular Arrhythmias in Patients with Right Ventricular Outflow Tract Tachycardia

Classification of Common Arrhythmias and Corresponding Treatment Principles in Communities

Advances in studies on arrhythmogenic right ventricular cardiomyopathy

Impaired heart rate variability in patients with arrhythmogenic cardiomyopathy: A multicenter retrospective study in China

Interpretation of 2015 European Society of Cardiology Guidelines for the Management of Ventricular Arrhythmias in Patients with Cardiomyopathies,Inherited Primary Arrhythmia Syndromes,paediatric Arrhythmias and Congenital Heart Disease, and the Prevention of Sudden Cardiac Death in Those Patients

Autonomic Neuromodulation for Preventing and Treating Ventricular Arrhythmias

Substrate-based mapping and ablation of ventricular tachycardia

Clinical analysis of arrhythmogenic right ventricular cardiomyopathy

Current Status and Challenges of Interventional Therapy for Diagnosis and Treatment of Arrhythmia in China

Competing risks of monomorphic vs. non-monomorphic ventricular arrhythmias in primary prevention implantable cardioverter-defibrillator recipients: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) study